<?xml version="1.0" encoding="utf-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0" xml:base="https://investors.myovant.com/">
  <channel>
    <title>Myovant Sciences Ltd. News Releases</title>
    <link>https://raw.githubusercontent.com/Gopichand413/digital-nirvana-ASNG/main/keyword1.html</link>
    <description>Myovant Sciences Ltd. News Releases</description>
    <language>en</language>
    
    <item>
  <title>Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors</title>
  <link>https://investors.myovant.com/news-releases/news-release-details/nancy-valente-md-joins-myovant-sciences-board-directors</link>
  <description>BASEL, Switzerland and LONDON, United Kingdom , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences  (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Nancy Valente , M.D. as an independent member of the company’s Board of</description>
  <pubDate>Mon, 08 Nov 2021 06:00:00 -0500</pubDate>
    <dc:creator>Myovant Sciences Ltd. News Releases</dc:creator>
    <guid isPermaLink="false">9631</guid>
    </item>
<item>
  <title>Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates</title>
  <link>https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-announces-financial-results-second-quarter</link>
  <description>Second fiscal quarter 2021 total revenues of $77.9 million ; net product revenue from U.S. sales of ORGOVYX ® of $18.7 million and MYFEMBREE ® of $0.6 million Estimated 8,000 cumulative patients treated with ORGOVYX through September 2021 , including patients on commercial and free drug;</description>
  <pubDate>Tue, 26 Oct 2021 06:55:00 -0400</pubDate>
    <dc:creator>Myovant Sciences Ltd. News Releases</dc:creator>
    <guid isPermaLink="false">9596</guid>
    </item>
<item>
  <title>Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress</title>
  <link>https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-and-pfizer-present-data-relugolix-combination</link>
  <description>BASEL, Switzerland and NEW YORK , Oct. 19, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences  (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the presentation of new data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone</description>
  <pubDate>Tue, 19 Oct 2021 06:58:00 -0400</pubDate>
    <dc:creator>Myovant Sciences Ltd. News Releases</dc:creator>
    <guid isPermaLink="false">9586</guid>
    </item>
<item>
  <title>Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021</title>
  <link>https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-host-second-fiscal-quarter-2021-earnings</link>
  <description>BASEL, Switzerland , Oct. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter</description>
  <pubDate>Tue, 12 Oct 2021 08:30:00 -0400</pubDate>
    <dc:creator>Myovant Sciences Ltd. News Releases</dc:creator>
    <guid isPermaLink="false">9566</guid>
    </item>
<item>
  <title>Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis</title>
  <link>https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-and-pfizer-announce-fda-acceptance-supplemental</link>
  <description>Filing in endometriosis is supported by data from the Phase 3 SPIRIT program FDA PDUFA target action date is May 6, 2022   BASEL, Switzerland and NEW YORK , Sept. 09, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences  (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S.</description>
  <pubDate>Thu, 09 Sep 2021 06:58:00 -0400</pubDate>
    <dc:creator>Myovant Sciences Ltd. News Releases</dc:creator>
    <guid isPermaLink="false">9421</guid>
    </item>
<item>
  <title>Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference</title>
  <link>https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-participate-2021-baird-global-healthcare</link>
  <description>BASEL, Switzerland , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences  (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global Healthcare Conference on September 15, 2021 . Company management will participate in a fireside</description>
  <pubDate>Wed, 01 Sep 2021 08:30:00 -0400</pubDate>
    <dc:creator>Myovant Sciences Ltd. News Releases</dc:creator>
    <guid isPermaLink="false">9391</guid>
    </item>
<item>
  <title>Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer</title>
  <link>https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-appoints-uneek-mehra-chief-financial-and</link>
  <description>BASEL, Switzerland , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and men, today announced the appointment of Uneek Mehra as Chief Financial and Business Officer of Myovant Sciences , Inc.  Mr.</description>
  <pubDate>Thu, 12 Aug 2021 16:01:00 -0400</pubDate>
    <dc:creator>Myovant Sciences Ltd. News Releases</dc:creator>
    <guid isPermaLink="false">9351</guid>
    </item>
<item>
  <title>Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates</title>
  <link>https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-announces-financial-results-first-quarter</link>
  <description>First fiscal quarter 2021 total revenues of $41.1 million ; net product revenue from U.S. sales of ORGOVYX ® of $10.5 million and MYFEMBREE ® of $1.1 million MYFEMBREE approved by the U.S. FDA in May 2021 as the first and only once-daily oral treatment for the management of heavy menstrual bleeding</description>
  <pubDate>Wed, 28 Jul 2021 06:55:00 -0400</pubDate>
    <dc:creator>Myovant Sciences Ltd. News Releases</dc:creator>
    <guid isPermaLink="false">9321</guid>
    </item>
<item>
  <title>Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids</title>
  <link>https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-announces-european-commission-approval-ryeqor</link>
  <description>RYEQO is the first and only once-daily long-term treatment for uterine fibroids in Europe Indication has no limitation for duration of use, as supported by safety and efficacy data from the Phase 3 LIBERTY program Gedeon Richter to commercialize RYEQO, starting in the second half of 2021; Myovant</description>
  <pubDate>Tue, 20 Jul 2021 02:00:00 -0400</pubDate>
    <dc:creator>Myovant Sciences Ltd. News Releases</dc:creator>
    <guid isPermaLink="false">9306</guid>
    </item>
<item>
  <title>Myovant Sciences to Host First Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on July 28, 2021</title>
  <link>https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-host-first-fiscal-quarter-2021-earnings</link>
  <description>BASEL, Switzerland , July 14, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences  (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter</description>
  <pubDate>Wed, 14 Jul 2021 08:30:00 -0400</pubDate>
    <dc:creator>Myovant Sciences Ltd. News Releases</dc:creator>
    <guid isPermaLink="false">9296</guid>
    </item>

  </channel>
</rss>
